M14-239

About this trial

Patient Profile

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy Doublet and/or an Immune Checkpoint Inhibitor, or EGFR TKI (if harbouring EGFR TKI activating mutation)

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: M14-239
Number: 18-49
Full Title:

Phase 2 Study of Telisotuzumab Vedotin (an Anti-c-Met Antibody Drug Conjugate) in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy Doublet and/or an Immune Checkpoint Inhibitor, or EGFR TKI (if harbouring EGFR TKI activating mutation).

Principal Investigator: Dr Emer Hanrahan
Type: Industry Sponsored
Sponsor:

AbbVie

Recruitment Started: Global:
Ireland:
Global Recruitment Target: 310
Ireland Recruitment Target: 2 patients/site/year